Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment

• Carmen Tur ,

  * E-mail: ctur@cem-cat.org

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Mar Tintoré,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Ángela Vidal-Jordana,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Denis Bichuetti,

  Affiliations Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain, Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil

  ⨯
• Pablo Nieto González,

  Affiliations Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain, Department of Neurology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain

  ⨯
• María Jesús Arévalo,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Georgina Arrambide,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Elisenda Anglada,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Ingrid Galán,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Joaquín Castilló,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Carlos Nos,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Jordi Río,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• María Isabel Martín,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Manuel Comabella,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Jaume Sastre-Garriga,

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
•  [ ... ],
• Xavier Montalban

  Affiliation Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• [ view all ]
• [ view less ]